Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr-/- mice
Source : https://www.sciencedirect.com/science/article/pii/S1537189123000320?via=ihub
In human plaques, BTK is mainly expressed in mast cells, B cells and myeloid cells. * Acalabrutinib dose-dependently inhibits bone marrow-derived mast cell activation. * Acalabrutinib treatment does not affect...
Conclusions/Relevance: Conclusively, BTK inhibition by Acalabrutinib alone did neither affect either mast cell activation nor early- and advanced atherosclerosis, despite the effects on follicular B cell maturation.
Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37094812/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Sustained long-term clinical and molecular remissions are achievable following ASCT.
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
Source : https://www.sciencedirect.com/science/article/pii/S0037196323000239?via=ihub
Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improve...
Conclusions: CP7 of IWWM-11 considers limited duration of therapy and novel-novel combinations to be the priority for the next generation of clinical trials. Central, validated testing of MYD88, CXCR4 and TP53 is crucial for trial reporting, and MYD88 and CXCR4 should be considered as stratification factors. In the frontline, BR and DRC may...
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
Source : https://www.sciencedirect.com/science/article/abs/pii/S0037196323000197?via=ihub
The main toxicities of CAR T-cell therapy are cytokine release syndrome (CRS), the neurological syndrome called Immune Effector Cell (IEC) Associated Neurologic Syndrome (ICANS), and cytopenias [1], [2], [3]. Hypogammaglobulinemia...
Conclusions/Relevance: The goal of this review is to present the infectious complications of CAR T-cell therapy, explain their temporal course and risk factors, and provide recommendations for their prevention, diagnosis, and management.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
Research Article | Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan...
Conclusions/Relevance: Orelabrutinib showed substantial efficacy and was well tolerated in patients with r/r MCL.